Reduced-Dose Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin Regimen as Graft-vs-Host Disease Prophylaxis in Patients With Hematological Malignancies Who Underwent Haplo-HSCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
British Journal of Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial
Br. J. Haematol 2022 Oct 06;[EPub Ahead of Print], W Zhang, R Gui, Y Zu, B Zhang, Z Li, Y Zhang, X Wang, S Guo, X Zhan, Y Fu, Y Song, J ZhouFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.